Healthcare provider profile · identity verified

Samuel Dean Detweiler, MD

Family Practice · NORTHVILLE, NY · NPI 1437299237

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	304	76
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	263	38
Atorvastatin Calcium	Atorvastatin Calcium	244	69
Lisinopril	Lisinopril	190	57
Gabapentin	Gabapentin	182	44
Omeprazole	Omeprazole	166	53
Rosuvastatin Calcium	Rosuvastatin Calcium	154	47
Alprazolam	Alprazolam	135	21
Albuterol Sulfate Hfa	Albuterol Sulfate	134	36
Amlodipine Besylate	Amlodipine Besylate	131	37
Duloxetine Hcl	Duloxetine Hcl	128	34
Metoprolol Succinate	Metoprolol Succinate	125	36
Zolpidem Tartrate	Zolpidem Tartrate	109	14
Hydrochlorothiazide	Hydrochlorothiazide	96	27
Metformin Hcl Er	Metformin Hcl	90	27
Sertraline Hcl	Sertraline Hcl	90	26
Tamsulosin Hcl	Tamsulosin Hcl	86	26
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	81	suppressed
Losartan Potassium	Losartan Potassium	80	25
Fluticasone Propionate	Fluticasone Propionate	79	44
Famotidine	Famotidine	78	29
Trazodone Hcl	Trazodone Hcl	76	23
Ozempic	Semaglutide	75	suppressed
Furosemide	Furosemide	65	21
Prednisone	Prednisone	64	41
Lorazepam	Lorazepam	63	suppressed
Eliquis	Apixaban	62	15
Pantoprazole Sodium	Pantoprazole Sodium	47	13
Baclofen	Baclofen	46	14
Metoprolol Tartrate	Metoprolol Tartrate	45	12
Simvastatin	Simvastatin	45	15
Oxycodone Hcl	Oxycodone Hcl	42	suppressed
Verapamil Er	Verapamil Hcl	41	suppressed
Synthroid	Levothyroxine Sodium	40	13
Atenolol	Atenolol	38	11
Ropinirole Hcl	Ropinirole Hcl	38	suppressed
Metformin Hcl	Metformin Hcl	37	suppressed
Montelukast Sodium	Montelukast Sodium	37	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	35	suppressed
Diclofenac Sodium	Diclofenac Sodium	34	11
Doxycycline Hyclate	Doxycycline Hyclate	33	24
Fluoxetine Hcl	Fluoxetine Hcl	33	suppressed
Jardiance	Empagliflozin	33	suppressed
Finasteride	Finasteride	32	11
Symbicort	Budesonide/Formoterol Fumarate	32	14
Clonazepam	Clonazepam	31	suppressed
Liothyronine Sodium	Liothyronine Sodium	31	suppressed
Trulicity	Dulaglutide	31	suppressed
Promethazine Hcl	Promethazine Hcl	30	suppressed
Meclizine Hcl	Meclizine Hcl	29	suppressed
Allopurinol	Allopurinol	28	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	28	suppressed
Fentanyl	Fentanyl	27	suppressed
Potassium Chloride	Potassium Chloride	26	suppressed
Pregabalin	Pregabalin	26	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	25	suppressed
Diazepam	Diazepam	23	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	23	suppressed
Ezetimibe	Ezetimibe	23	suppressed
Mirtazapine	Mirtazapine	23	suppressed
Valsartan	Valsartan	23	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	22	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	22	suppressed
Azelastine Hcl	Azelastine Hcl	21	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	16
Mounjaro	Tirzepatide	20	suppressed
Victoza 3-Pak	Liraglutide	20	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	19	suppressed
Glipizide Er	Glipizide	19	suppressed
Novolog	Insulin Aspart	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	19	suppressed
Pravastatin Sodium	Pravastatin Sodium	19	suppressed
Ventolin Hfa	Albuterol Sulfate	19	suppressed
Carvedilol	Carvedilol	18	suppressed
Glipizide	Glipizide	18	suppressed
Incruse Ellipta	Umeclidinium Bromide	18	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Alendronate Sodium	Alendronate Sodium	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	suppressed
Varenicline Tartrate	Varenicline Tartrate	17	suppressed
Azithromycin	Azithromycin	16	12
Breyna	Budesonide/Formoterol Fumarate	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	16	11
Citalopram Hbr	Citalopram Hydrobromide	15	suppressed
Lansoprazole	Lansoprazole	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Torsemide	Torsemide	15	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	14	suppressed
Farxiga	Dapagliflozin Propanediol	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Enbrel	Etanercept	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Xifaxan	Rifaximin	13	suppressed
Ambien Cr	Zolpidem Tartrate	12	suppressed
Clobetasol Propionate	Clobetasol Propionate	12	suppressed
Clotrimazole	Clotrimazole	12	suppressed
Donepezil Hcl	Donepezil Hcl	12	suppressed
Olopatadine Hcl	Olopatadine Hcl	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Clopidogrel	Clopidogrel Bisulfate	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error